From Tricorders to Tribbles: When Sci-Fi Becomes a Patent Filing
It is a truth almost universally acknowledged—except, perhaps, in FDA review meetings—that no credible scientist gets funded anymore
The shape of cures to come: AlphaFold’s structural revolution in drug discovery
The decades-long puzzle of protein folding
In the pantheon of scientific challenges, few have loomed as large or as stubborn
No Cure Without Coverage: Digital Health’s Reimbursement Riddle
When a small Berlin startup launched an obesity therapy app a few years ago, investors hailed it as a potential
Real-World Data (RWD): The Messy Yet Essential Future of Healthcare
Real-World Data (RWD) is the equivalent of field notes in anthropology: messy, unstructured, but full of valuable insights about how
Of CEOs, Titles, and Other Startup Ailments: A Treatise on the Cult of Empty Authority
Startups are curious beasts. They move fast, break things, raise millions, and yet remain spectacularly unable to define who is
The Biotech Platform Company Model: De-Risking Drug Development or VC Mirage?
Introduction: Platforms, Promise, and the VC Paradox
Biotechnology has always been a high-stakes endeavor, with the odds stacked against any
The Dusty Tools of Management: Why We Still Cling to Outdated Frameworks
If you’ve been through business school, corporate training, or an executive retreat, chances are you’ve encountered the holy
“We Use the Method™”: How to Charge €400/hr for a Matrix and Get Away With It
Strategy was once a noun. Then someone turned it into a 2x2 matrix and started charging €400/hour for it.
The Rise and Fall of bluebird bio: A Gene Therapy Pioneer’s Journey
Foundations of a Gene Therapy Pioneer (1992–2010)
bluebird bio began not as the vibrant name suggests, but as a
Advisers Advise, Ministers Decide: A Founder’s Manifesto
In the spirit of Thatcher—and with apologies to everyone who just spat out their ethically sourced oat milk—here’
